c-Met targeted therapy of cholangiocarcinoma

Matei P. Socoteanu, Frank Mott, Gianfranco Alpini, Arthur E. Frankel

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Cholangiocarcinoma continues to be a challenging (disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase H trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.

Original languageEnglish (US)
Pages (from-to)2990-2994
Number of pages5
JournalWorld Journal of Gastroenterology
Issue number19
StatePublished - May 21 2008
Externally publishedYes


  • Chemotherapy
  • Cholangiocarcinoma
  • Target therapy
  • c-Met

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'c-Met targeted therapy of cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this